How it works
BrainZell's platform combines high-throughput brain organoid experiments with advanced computational modeling. Large-scale biological datasets generated from organoids are analyzed using AI to identify disease mechanisms, discover novel drug targets, and predict therapeutic responses earlier than ever. A unique “lab-in-the-loop” system continuously connects biological experiments with our AI models, enabling rapid testing of hypotheses and refinement of predictive algorithms.
Our platform is designed to handle large volumes of experiments simultaneously, drastically reducing turnaround times and accelerating the path to discovering new drug candidates.
Our models have possibility for microglia co-culture, enabling the discovery of the neuroimmune aspects of disease progression and treatment response.
Customized hiPSCs Sourcing
Choosing what works best for a specific application
a diverse range of genetic backgrounds from established biobanks.
collaborating with clinical partners to obtain patient-specific cells.
iPSC lines provided by collaborating partners.
Assays
Our platform enables treatments ranging from single exposure to long term and repeated exposures.
Tests per week
Organoids
